Even as researchers at Oxford University have begun testing their potential vaccine against COVID-19 on a small group of human volunteers, they hope to expand the tests soon after getting positive results from the initial trial.
"Oxford University initiated trials of the COVID-19 vaccine on 23 April 2020 and plans to vaccinate 800 volunteers in the UK over the next month," the Oxford Vaccine Group said.
"If the trial is successful in the UK, then the Oxford team will approach scientists in the Kenya Medical Research Institute (KEMRI) and will approach the Government of Kenya for permission to evaluate in Kenya," it added in an update.
A vaccine candidate for COVID-19 was identified by researchers from the Oxford Vaccine Group and Oxford's Jenner Institute.
The potential upcoming vaccine, ChAdOx1 nCoV-19, is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein.
By vaccinating with ChAdOx1 nCoV-19, the scientists hope to make the body recognise and develop an immune response to the Spike protein that will help stop the SARS-CoV-2 virus from entering human cells and therefore prevent infection.
According to a report in the New York Times on Monday (27 April), the scientists plan to test the vaccine in trials involving more than 6,000 people by the end of May.
And if the trials show positive results, the first few million doses of the vaccine may be available by September, several months ahead of any of the other efforts announced so far, said the report.
In experiments conducted at the US National Institutes of Health's Rocky Mountain Laboratory in Montana last month, single doses of the Oxford vaccine proved effective in protecting rhesus macaque monkeys against the virus which is responsible for the pandemic.
This has raised hope that the vaccine might work to protect humans as well.
However, it is too early to say which potential vaccine will prove to be the most successful in protecting people against COVID-19 as it may take some time for clinical trial data to become available.
More than 70 research efforts are on currently to develop a vaccine against COVID-19.
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.